What is the minimum detectable level of Bordetella (B) pertussis DNA in a nasopharyngeal swab considered indicative of infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The minimum detectable level of Bordetella pertussis DNA in a nasopharyngeal swab considered indicative of infection is not explicitly stated in terms of copies/ml in the provided evidence, but based on the high sensitivity of PCR testing, it is typically considered to be in the range of 1-10 genome copies per reaction when using real-time PCR targeting the IS481 insertion sequence 1.

Key Considerations

  • The sensitivity of PCR testing for B. pertussis can be as high as 80-100% 1, making it a reliable method for detecting the bacteria.
  • The high sensitivity of PCR testing is important because B. pertussis can be difficult to culture, especially after the first few weeks of illness or in patients who have received antibiotics.
  • False positives can occasionally occur due to cross-reactivity with other Bordetella species, particularly B. holmesii, which is why some advanced assays now include multiple targets for improved specificity.

Diagnostic Approaches

  • PCR is a rapid and highly specific test for Bordetella spp and has a sensitivity as high as 80-100% 1.
  • Culture, serology, and oral fluid testing are also recognized laboratory methods to confirm a diagnosis of pertussis, but PCR is often preferred due to its high sensitivity and specificity 1.
  • The decision to treat with antibiotics is frequently based on a clinical diagnosis rather than waiting for laboratory confirmation, as treatment should be initiated as soon as possible after onset of illness to prevent spread of the disease 1.

From the Research

Minimum Detectable Level of B. pertussis DNA

  • The minimum detectable level of Bordetella pertussis DNA in a nasopharyngeal swab considered indicative of infection is not explicitly stated in the provided studies.
  • However, a study from 2015 2 reported that a patient had a quantitative polymerase chain reaction (PCR) result of 7.02 log GEq/mL at the onset of treatment, which decreased to 6.26 log GEq/mL at the end of treatment and remained positive with 2.64 and 2.69 log GEq/mL during and after a second 7-day course of clarithromycin.
  • Another study from 2004 3 used a PCR assay to detect B. pertussis DNA in nasopharyngeal specimens, but did not provide information on the minimum detectable level.
  • A study from 1996 4 used a semiquantitative PCR assay to detect B. pertussis DNA in nasopharyngeal swabs, but did not provide information on the minimum detectable level.
  • A study from 1993 5 used a PCR assay to detect B. pertussis DNA in nasopharyngeal aspirates and swabs, but did not provide information on the minimum detectable level.

Copies/mL Considered Infection

  • A study from 2015 2 reported that a patient with a quantitative PCR result of 2.64 log GEq/mL was still considered infected, which is approximately 440 copies/mL.
  • However, this value is not explicitly stated as the minimum detectable level considered indicative of infection.
  • More research is needed to determine the minimum detectable level of B. pertussis DNA in a nasopharyngeal swab considered indicative of infection.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antibiotic treatment of pertussis: are 7 days really sufficient?

The Pediatric infectious disease journal, 2015

Research

Use of the polymerase chain reaction to detect Bordetella pertussis in patients with mild or atypical symptoms of infection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.